pharmaceutical data

Controversy heats up over pharmacy benefit manager DIR feesPBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.
More Billion-Dollar Drugs, Faster Approvals, and Other Pharmaceutical Trends
More Billion-Dollar Drugs, Faster Approvals, and Other Pharmaceutical TrendsWhat’s been going on in the biopharmaceutical industry?
Payers strategize to manage opioid useHow managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.
Managed care pharmacy survey findings 2016To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, conducted its first-ever pharmacy survey during the second quarter of 2016.
Top 4 pharmacy trends healthcare executives should watch
Top 4 pharmacy trends healthcare executives should watchManaged Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results.
Addressing rising pharma costs: A roundtable discussionAt the AMCP16 conference, Managed Healthcare Executive invited some of the nation’s leading pharmacy and managed care experts to join us to discuss some of the most critical managed care pharmacy challenges facing the industry.
Top 10 sessions to attend at the AMCP Annual Meeting 2016This year’s Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting 2016, held April 19 to 22 in San Francisco, will feature several sessions of important to managed care professionals. Here are our top 10 recommendations.
Pharma responds to critics with new drug adsPhRMA ad campaign features new patient and researcher stories.
Report: Specialty drugs unaffordable for consumersA new AARP report shows that the rapid rise in cost of specialty drugs exceeds median family income.
Top 5 fastest-growing drug firmsFortune describes the 5 fastest-growing US pharmaceutical manufacturers.